PORTLAND, ORE. – New research has uncovered “a new kid on the block” of genes underlying epidermolysis bullosa simplex (EBS), which may someday...
Under My Skin
My grandson is almost 3. He is, of course, very advanced in many areas, including self-awareness.At the moment he is suffering from Fifth Disease...
SYDNEY – Just over half of patients with lichen planopilaris in a medical record review responded to first-line therapies, but response rates...
The approval of tocilizumab was made with breakthrough therapy and priority review designations.
PORTLAND - The effects of a topical JAK inhibitor on facial vitiligo in four patients were promising.
PORTLAND, ORE. – A study of patients with pyoderma gangrenosum provides information about comorbidities to look out for in this population.
News from the FDA/CDC
The risk of lower limb amputation associated with canagliflozin is now great enough to receive a boxed warning.
The investigational agent CC-220 showed some efficacy but also important safety caveats in a 12-week, phase II trial.
SYDNEY, AUSTRALIA – Satisfaction with the effects of botulinum toxin therapy for axillary hyperhidrosis was high in a retrospective study of...